Open AccessDexrazoxane decreases the cardiotoxic effects of doxorubicin in osteosarcoma patients without increasing mortality from secondary malignant neoplasms
Author(s) -
Thomas S Przybycien
Publication year - 2021
Publication title -
clinical research in practice
Language(s) - English
Resource type - Journals
ISSN - 2379-4550
DOI - 10.22237/crp/1622160360
Subject(s) - dexrazoxane , osteosarcoma , medicine , doxorubicin , blood cancer , chemotherapy , oncology , cancer , clinical oncology , cancer research , breast cancer , anthracycline